 In 1992, they first published on lamivudine (3TC) in Antimicrobial Agents and Chemotherapy.This drug became one of the most successful antiviral agents used to combat HIV as part of fixed-dose combinations (including Combivir, Trizivir, Epzicom, and Triumeq).Combination therapies incorporating 3TC quickly became the standard of care, with safe and effective nucleoside reverse transcriptase (RF) inhibitors, such as 3TC and its related cousins, serving as the cornerstones of combination chemotherapy.